Stockreport

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor [Yahoo! Finance]

IDEAYA Biosciences, Inc.  (IDYA) 
Last ideaya biosciences, inc. earnings: 3/24 06:00 am Check Earnings Report
PDF IDE275 (GSK959) has demonstrated a potential best-in-class preclinical profile in the MSI-H setting, with a unique binding mode from previously reported WRN inhibitors [Read more]